Factors Affecting Dabrafenib/Trametinib Outcomes in Melanoma Identified
November 22nd 2015In the largest-to-date analysis of treatment-naïve metastatic melanoma patients with BRAF V600 mutations treated with dabrafenib and trametinib, researchers have found that baseline LDH levels and number of disease sites were the most significant factors affecting survival.
Read More